Billets de Michelle Dawson

Billet publié sur Twitter/X le 16/04/2023 15:14

Twitter/X Publication avec DOI crossref Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet

Liens cités structurés

1 ressource citée

Publication avec DOI Récupéré Publication crossref

Hsiang-Yuan Lin, Elia Abi-Jaoude, Pushpal Desarkar, Wei Wang, Stephanie H. Ameis, Meng-Chuan Lai, Yona Lunsky, Tarek K. Rajji (2023). Nabilone treatment for severe behavioral problems in adults with intellectual and developmental disabilities: Protocol for a phase I open-label clinical trial. PLOS ONE, 18(4), e0282114. Public Library of Science (PLoS).

Date de publication
12/04/2023
Identifiant
10.1371/journal.pone.0282114
Auteurs
Hsiang-Yuan Lin, Elia Abi-Jaoude, Pushpal Desarkar, Wei Wang, Stephanie H. Ameis, Meng-Chuan Lai, Yona Lunsky, Tarek K. Rajji
Source
PLOS ONE
Détails
18(4), e0282114
Type de référence
article
Éditeur
Public Library of Science (PLoS)
Source de métadonnées
crossref

Résumé

Severe behavioral problems (SBPs) are common contributors to morbidity and reduced quality of life for adults with intellectual and developmental disabilities (IDD) and their families. Current medications for SBPs show equivocal effectiveness and are associated with a high risk of side effects. New and safe treatments are urgently needed. While preliminary studies suggest that medical cannabinoids, particularly the synthetic cannabinoid nabilone, are plausible treatment options for SBPs in adults with IDD, data on the tolerability, safety and efficacy of nabilone in this population has never been investigated. Thus, we propose this first-ever Phase I pre-pilot open-label clinical trial to obtain preliminary data on the adherence, tolerability and safety profiles of nabilone in adults with IDD, and explore changes in SBPs pre- to post-treatment. We hypothesize that nabilone has favorable tolerability and safety profile for adults with IDD. The preliminary results will inform the next-stage pilot randomized controlled trials, followed by fully powered clinical trials eventually. This research helps fill the evidence gap in the use of cannabinoids in individuals with IDD to meet the needs of patients, families, and service providers.

Auteur·ices de l’étude dans cette référence citée